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Magnetic resonance spectroscopy 
Ultra-high field MRI 
a b s t r a c t 
Magnetic Resonance Spectroscopy (MRS) allows for the non-invasive quantification of neurochemicals and has 
the potential to differentiate between the pathologically distinct diseases, multiple sclerosis (MS) and AQP4Ab- 
positive neuromyelitis optica spectrum disorder (AQP4Ab-NMOSD). In this study we characterised the metabolite 
profiles of brain lesions in 11 MS and 4 AQP4Ab-NMOSD patients using an optimised MRS methodology at ultra- 
high field strength (7T) incorporating correction for T2 water relaxation differences between lesioned and normal 
tissue. 
MS metabolite results were in keeping with the existing literature: total N-acetylaspartate (NAA) was lower in le- 
sions compared to normal appearing brain white matter (NAWM) with reciprocal findings for myo -Inositol. An un- 
expected subtlety revealed by our technique was that total NAA differences were likely driven by NAA-glutamate 
(NAAG), a ubiquitous CNS molecule with functions quite distinct from NAA though commonly quantified together 
with NAA in MRS studies as total NAA. Surprisingly, AQP4Ab-NMOSD showed no significant differences for total 
NAA, NAA, NAAG or myo -Inositol between lesion and NAWM sites, nor were there any differences between MS 
and AQP4Ab-NMOSD for a priori hypotheses. Post-hoc testing revealed a significant correlation between NAWM 
Ins:NAA and disability (as measured by EDSS) for disease groups combined, driven by the AP4Ab-NMOSD group. 
Utilising an optimised MRS methodology, our study highlights some under-explored subtleties in MRS profiles, 
such as the absence of myo -Inositol concentration differences in AQP4Ab-NMOSD brain lesions versus NAWM 
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(  . Introduction 
Magnetic Resonance Spectroscopy (MRS) allows for the non-invasive
uantification of neurochemicals, and therefore has the potential to dif-
erentiate between pathologically distinct diseases. This is perhaps espe-
ially important in circumstances where clinical syndromes may over-
ap but treatment strategies are distinct. In particular, there is interest in
tilising MRS to differentiate the primary astrocytopathy Aquaporin-4
ntibody positive Neuromyelitis Optica Spectrum Disorders (AQP4Ab-
MOSD) ( Fujihara, 2011 ) from the clinically similar but pathologically
istinct disorder, Multiple Sclerosis (MS), which is believed to be a
hronic inflammatory demyelinating disorder with secondary neurode-
eneration ( Lucchinetti et al., 2014 ; Wingerchuk et al., 2015 ). In addi-
ion, where MRS metrics prove sensitive to the underlying pathology in
 disease state, they can inform our understanding of that pathology,
nd potentially be developed as biomarkers for future pharmacological
tudies. 
MRS studies in MS consistently report a core pattern of findings.
ompared to healthy control brain tissue, lesions of all ages show re-
uced total N-acetyl aspartate (tNAA) likely reflecting decreased neu-
onal mitochondrial activity, and raised myo -Inositol-containing com-
ounds (Ins), commonly taken to reflect glial activity ( Brex et al.,
000 ; Ciccarelli et al., 2013 ; Miller et al., 2003 ). A similar pattern of
hanges is found in MS normal appearing white matter (NAWM) ver-
us healthy controls, though to a smaller degree ( De Stefano et al.,
007 ; Fernando et al., 2004 ; Helms et al., 2000 ; Miller et al., 2003 ).
n addition to changes in specific metabolites, the relative concentra-
ions of some MRS metabolites have also been correlated with clinical
etrics. The relative concentration of myo -Inositol and tNAA in NAWM
Ins:tNAA), which provides an insight into the relative activity of glia
nd neurons within a given region, has been shown to predict disease
rogression in MS. It has been hypothesised to be a sensitive index that
ncapsulates both the damaging immune-mediated gliosis (increase in
yo -Inositol) and the disabling neurodegenerative axonal loss (reduc-
ion in NAA) that are known features of MS pathology ( Llufriu et al.,
014 ; Miller DH, 2014 ). 
In patients with AQP4Ab-NMOSD, there is little or no evidence
or a difference in either tNAA (i.e. NAA + NAAG) or myo -Inositol in
ormal appearing white matter compared to healthy controls ( Aboul-
nein et al., 2010 ; Bichuetti et al., 2008 ; Kremer et al., 2015 ), rais-
ng the possibility that myo -Inositol and tNAA may be sensitive dis-
riminators between AQP4Ab-NMOSD and MS. However, no studies
o date have studied MRS-quantified neurochemicals within AQP4Ab-
MOSD lesions in the brain. A single study has examined MRS-derived
eurochemical profiles in AQP4Ab-NMOSD lesions within the spinal
ord and demonstrated significantly lower myo -Inositol in AQP4Ab-
MOSD lesions compared with both MS cord lesions and healthy con-
rols ( Ciccarelli et al., 2013 ), consistent with previously observed astro-
yte damage and loss in AQP4Ab-NMOSD lesions. Ciccarelli et al. also
emonstrated, in line with existing literature, a substantial decrease in
NAA in MS lesions compared with healthy controls, but no significant
ifference in tNAA between AQP4Ab-NMOSD lesions and either MS le-
ions or healthy controls. 
Here, we wished to see whether MRS could distinguish between
QP4Ab-NMOSD and MS lesions in the brain. However, there are a
umber of technical difficulties in performing MRS in the context of neu-
ological disease that are important to overcome in order to accurately
ddress this question. In particular, lesioned tissue has a longer T2 than
on-lesioned tissue, due to its greater water content ( Zimmerman et al.,
986 ), which, if not compensated for (e.g. by using a short TE and T2 ∗ 
easurement), will directly influence metabolite quantification. In addi-
ion, it is important to fully separate neurochemicals with highly similar
pectral resonances but disparate physiological functions, for example
AA and the closely chemically related, but functionally distinct, NAA-
lutamate (NAAG), often combined in the MRS metric tNAA. This is par-
icularly important in the context of neurodegeneration, as NAA reflects2 euronal mitochondrial function, whereas NAAG acts as a neuromodu-
ator ( Baslow, 2000 ; Birken and Oldendorf, 1989 ; Neale et al., 2000 ). It
s therefore difficult to clearly interpret changes in the tNAA metric in
erms of the underlying pathology. 
We therefore exploited recent advances in MRS methodology to
tudy pathological differences between AQP4Ab-NMOSD and MS le-
ions. We used an ultra-high field (7T) scanner, to allow separation
etween NAA and NAAG, something not easily achievable at 3T, and
odelled multiple water T2-relaxation times to compensate for lesion-
elated effects on metabolite quantification ( Helms, 2001 ), approaches
hat have been little used in this context before now. 
We wished to test the hypotheses that (1) myo -Inositol would be
igher in MS brain lesions than AQP4Ab-NMOSD brain lesions, reflect-
ng the likely increased astrocytic damage in AQP4Ab-NMOSD com-
ared to the reciprocal astrogliosis found in MS lesions, and (2) that NAA
tNAA, NAA & NAAG) would be higher in the normal appearing white
atter in AQP4Ab-NMOSD patients compared with MS patients, in line
ith the relative lack of extra-lesional neurodegeneration in AQP4Ab-
MOSD ( Matthews et al., 2015 ). Within diseases we also hypothesised
hat (3) NAA (tNAA, NAA & NAAG) would be greater in NAWM than
esion sites in line with expected neuronal loss in lesions, and that (4)
yo -inositol would be differentially greater in MS brain lesion versus
AWM sites and lower in AQP4Ab-NMOSD lesion versus NAWM sites
eflecting the contrasting gliotic and astrocytopathic nature of lesions
n these two conditions (see Box 1 for summary of hypotheses). 
. Methods 
.1. Subjects 
Eleven patients with clinically diagnosed relapsing-remitting mul-
iple sclerosis (RRMS) and four patients with AQP4Ab-NMOSD gave
heir written informed consent to participate in the study, under local
thics board approval (Oxfordshire REC A 10/H0604/99; Berkshire REC
3/SC/0238). A twelfth multiple sclerosis patient was scanned but later
xcluded as found to fit secondary-progressive multiple sclerosis diag-
ostic criteria. In addition to MR scanning, patients underwent a short
linical consultation and neurological examination including EDSS scor-
ng. Current medications were recorded. Minimum lesion age was cal-
ulated as the time from the oldest clinical brain MRI to contain the
argeted lesion, and only lesions > 3 months old were included. 
.2. MR acquisition 
MR was performed on a 7T Siemens MAGNETOM system (Siemens,
rlangen, Germany) equipped with a Nova Medical 32 channel receive
rray head coil. Two MRS volumes-of-interest (VOIs) were acquired per
ubject: one targeting a chronic, T2-hyperintense, T1-hypointense white
atter lesion ( > 3 months old, confirmed on historical clinical MRIs)
nd another centred on a contralateral area of normal appearing white
atter (NAWM; a majority white-matter voxel, avoiding as much grey
atter and cerebrospinal fluid as possible), positioned as close as pos-
ible to contralateral reflection-symmetrical with the lesion voxel. The
pectroscopy voxel volume was 15 × 15 × 15 mm 3 . Dielectric pads were
ot used. 
Spectroscopy voxels were manually positioned by reference to a
-dimensional 1 mm isotropic T2-weighted fluid-attenuated inversion
ecovery (FLAIR) image (1 mm isotropic, TR = 5 s, TE = 272 ms,
I = 1.8 s) (See Supplemental Figure 1 for individual voxel locations).
irst- and second-order shims were first adjusted by gradient-echo shim-
ing ( Shah et al., 2009 ). The second step involved only fine adjustment
f first order shims using FASTMAP ( Gruetter and Tkáč, 2000 ). Spec-
ra were acquired using a Stimulated Echo Acquisition Mode (STEAM)
ulse sequence (TE = 11 ms, TR = 5 s, number of transients = 64) with
ariable power radiofrequency pulses with optimized relaxation delay
VAPOUR), water suppression and outer volume saturation ( Emir et al.,


























































































































M  012 ). Unsuppressed water spectra acquired from the same voxel were
sed to remove residual eddy current effects and to reconstruct the
hased array spectra (one transient per echo). Metabolite T2-relaxations
ere not calculated as these would have pushed scan time beyond the
easible limit for our clinical group with comorbid disability and pain. 
Finally, fully relaxed unsuppressed water signals were acquired at
Es ranging from 11 to 4000 ms (TR = 15 s) to estimate the cerebrospinal
uid (CSF) contribution to each VOI (see below). A whole-brain 3-
imensional T1-MPRAGE (1 mm isotropic, TR = 2.2 s, TE = 282 ms)
as also acquired to evaluate T1 hypo-intensity in lesions and used in
onjunction with T2-weighted images to (1) aid manual segmentation
f lesions and (2) for automated multi-channel segmentation to calcu-
ate partial volumes of grey and white matter (FSL FAST; Supplemental
able 2) ( Zhang et al., 2001 ). 
.3. MRS analysis 
Absolute metabolite concentrations were obtained relative to an un-
uppressed water spectrum acquired from the same VOI. The transverse
elaxation times (T2) of tissue water and percent CSF contribution to
he VOI were obtained by fitting the integrals of the unsuppressed water
pectra acquired in each VOI at different TE values with a biexponential
t ( Piechnik et al., 2009 ), with the T2 of CSF fixed at 565 ms ( Joers et al.,
018 ) and three free parameters: T2 of tissue water, amplitude of tissue
ater, and amplitude of CSF water (CSF fractions can be found in Sup-
lemental Table 1). Absolute metabolite concentrations were calculated
y utilizing the unsuppressed water and correcting for tissue water and
SF content. The T2 relaxation of tissue water was taken into account
n the LCModel fitting by using each VOI’s tissue water T2 relaxation
stimations. 
LCModel ( Provencher, 2001 ) was used for spectral analysis and
uantification. The model spectra of alanine (Ala), aspartate (Asp),
scorbate/vitamin C (Asc), glycerophosphocholine (GPC), phospho-
holine (PC), Cr, phosphocreatine (PCr), 𝛾‐aminobutyric acid (GABA),
lucose (Glc), Gln, Glu, GSH, myo ‐Ins, lactate (Lac), NAA, N ‐ acety-
aspartylglutamate (NAAG), phosphoethanolamine (PE), scyllo ‐inositol
scyllo ‐Ins) and taurine (Tau) were generated on the basis of previously
eported chemical shifts and coupling constants ( Govindaraju et al.,
000 ; Tkac, 2008 ) by using GAMMA/PyGAMMA simulation library of
ESPA for carrying out the density matrix formalism (VErsatile Simula-
ion, Pulses and Analysis) ( Soher et al., 2011 ). See Fig. 1 . All metabolites
hat underwent group analyses (Ins, NAA, NAAG and tNAA) had Cramér-
ao lower bounds (CRLBs) estimated error of metabolite quantification
ess than 20%. 
.4. Statistics 
Group characteristics of age, disease duration, EDSS and minimum
ge of lesions were compared using permutation-based unpaired t-tests;
ex and ethnicity were compared using chi-square with Yates correction.
ermutation-based paired t-tests were used to compare mean T2-water
stimates and measures of spectral quality. Permutation-based unpaired
wo-sample t-tests were used to compare lesions and areas of NAWM
cross groups (hypotheses 1 and 2). Permutation-based one-sample t-
ests were performed to test individual lesion and NAWM metabolite
oncentration differences within disease groups (hypotheses 3 and 4).
ll group-level t-tests were computed using non-parametric permuta-
ion testing in FSL’s PALM ( Alberton et al., 2020 ; Jenkinson et al.,
012 ; Winkler et al., 2016 ). The maximum possible number of permuta-
ions (or ‘shufflings’) were used. This equated to 2048 shufflings (sign-
ips) for within MS comparisons, 16 shufflings (sign-flips) for within
QP4Ab-NMOSD and 1365 shufflings (permutations) for between dis-
ase group comparisons. Note that the number of shufflings imposes an
pper bound on the smallest possible p-value, that can only be as small
s 1/(#permutations). Thus, for comparisons within AQP4Ab-NMOSD,
he largest possible p-value is 1/16 = 0.0625. We ran statistical tests3 or metabolite comparisons in three batches (the fewest number that
ata structure and test methodology would allow) to allow for family
ise error rate correction. The three batches were: permutation-based
npaired t-tests for MS and AQP4Ab-NMOSD comparisons, permutation-
ased one-sample t -test for AQP4Ab-NMOSD lesion versus NAWM dif-
erences and permutation-based one-sample t-tests for MS lesion versus
AWM differences. In order to test our directionally specific hypotheses,
ll a priori group-level t-tests were one-tailed, however all one-tailed t-
ests were also run in the unexpected (opposite) direction and corrected
or both directions (this is statistically equivalent to a two-tailed t-tests,
ut allows for meaningful comment on the uncorrected one-tailed value
ssociated with our a priori hypotheses). 
Tests of correlation were limited to common associations described
n the literature, namely disability’s association with NAA:tCr (normal
ppearing brain tissue & lesions) ( Khan et al., 2016 ; Mainero et al.,
001 ), Ins:NAA (normal appearing white and grey matter) ( Llufriu et al.,
014 ; Miller DH, 2014 ) and GABA (normal appearing grey matter)
 Cawley et al., 2015 ), and disease duration’s association with Ins, NAA,
r, tCr and tCho (normal appearing brain tissue) ( Kirov et al., 2013 ).
orrelations were evaluated visually and with R-square (R 2 ), how-
ver due to low numbers of participants and the relatively large num-
er of tests, p-values were not calculated except for post-hoc testing
f Pearson’s correlation coefficient in the case of mI:NAA vs EDSS
See supplemental figure 3). Pearson’s correlations performed in R (R
ore Team, 2017 ; Wickham, 2016 ). 
. Results 
Patient characteristics are listed in Table 1 . Three of the four
QP4Ab-NMOSD participants were Afro-Caribbean and one was Asian,
n line with the non-Caucasian predominance in this disease. One MS
articipant was Afro-Caribbean, the remainder were Caucasian. All le-
ions studied were hyper-intense on the FLAIR image and hypo-intense
n the T1 weighted image. The minimum age of the brain lesions ranged
rom 132 days to 9 years. 
.1. MRS quality metrics 
We first wanted to ensure that there were no systematic differences
n the quality of the LCModel fit between the NAWM and lesion VOIs.
eported CRLB estimates were generally low in all cases, however the
umber not reaching our inclusion threshold of CRLB < 20% is indicated
or each metabolite in Supplemental Tables 3A and B. We then wished
o ensure that there was no significant difference in the quality of fit be-
ween NAWM and lesion groups. Statistical analyses demonstrated no
ifferences, when tests were corrected for multiple comparisons (paired
 -test p-values, 𝛼 = 0.05, Bonferroni threshold = 0.05/24 = 0.0021;
.0021 < p < 0.05: Asp- p = 0.040; p > 0.05 for all other metabolites; see
upplemental Table 3A and B and Supplemental figure 2). 
.2. T2 differences between lesions and normal-appearing tissue are 
elevant for metabolite quantification 
There was no difference between the LCModel estimated line-widths
Full Width Half Maximum, FWHM) and Signal-to-Noise ratios (S/N)
f the spectra from the NAWM and lesioned tissue ( Table 2 ). How-
ver, estimated T2-water relaxation time was higher in lesion vox-
ls than for NAWM voxels, reflecting the higher free-water content in
his tissue ( Table 2 ). We therefore went on to quantify neurochemi-
als in MS and AQP4Ab-NMOSD lesions and NAWM spectra using T2-
orrected spectra. There was no estimated T2-water relaxation time dif-
erence between disease groups for combined measures, or for lesions or
AWM voxels alone ( Table 2 ). There was also no difference in average
M/GM partial-volume in NAWM voxels between disease groups (seg-
ented using multi-channel FSL FAST on T2 and MPRAGE; WM mm 3 ,
S vs AQP4Ab-NMOSD: 2983.5 ± 259.2 vs 3081 ± 169.3 (mean ± sd),
G. Tackley, Y. Kong, R. Minne et al. NeuroImage 238 (2021) 118225 
Fig. 1. Example spectra and voxel placement from single subject. 
A. Raw spectrum data, LCModel fit (for average spectra and individual metabolites with CRLB < 20%), residual-error and baseline for example participant (no. 20); 
B. Example voxel placement (lesion outlined in black and NAWM region outlined in orange) for same subject; C. Comparison of fitted (and baseline subtracted) lesion 
and NAWM spectra showing differences in mI and NAA peaks, again for same subject. 
ppm, parts per million; Ins, myo -inositol; NAA, N-aspartylaspartate. 
Table 1 
Demographics and clinical features. 
MS NMO All 
Total n 11 4 15 
Age, yrs, median (min–max) 43 (28–60) 38 (24–40) 40 (24–60) 
Female, n (%) 7 (63.6) 3 (75) 10 (66.7) 
Race 
Afro-caribbean (%) 1 (9.1) ∗ ∗ 3 (75) ∗ ∗ 4 (26.7) 
Caucasian (%) 10 (90.9) ∗ ∗ 0 (0) ∗ ∗ 10 (66.7) 
Asian (%) 0 (0) ∗ ∗ 1 (25) ∗ ∗ 1 (6.7) 
Disease duration, yrs, mean (sd) 6.8 (5.5) 8.9 (3.2) 7.3 (5.1) 
EDSS, median (min-max) 2 (0–6) 3.75 (0–6) 2.5 (0–6) 
Minimum age of lesion, months, mean (sd) 36 (33.3) ∗ 86.6 (27.1) ∗ 49.5 (38.9) 
On treatment, n (%) 8 (72.7) 4 (100) 12 (80) 
∗ p < 0.05 for MS vs NMO permutation-based t -test comparison. 
∗ ∗ p < 0.05 for MS vs NMO chi-square comparison (with Yates correction). 
4 
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Table 2 
Estimated T2-water, LCmodel estimated FWHM and SNR. 
Lesion NAWM 
MS NMOSD Combined MS NMOSD Combined 
T2 water (ms) 43.3 (2.7) ∗ ∗ 44.7 (2.7) 43.7 (2.8) ∗ 40.1 (2.9) ∗ ∗ 39.3 (1.6) 39.9 (2.6) ∗ 
FWHM (ppm) 0.03 (0.004) 0.03 (0.005) 0.03 (0.004) 0.03 (0.004) 0.03 (0.002) 0.03 (0.003) 
S/N 25.9 (4.8) 25 (7.3) 25.7 (5.6) 28.8 (4.3) 27 (2.9) 28.3 (4) 
FWHM, full width half maximum. 
S/N, signal to noise ratio. 
Permuted paired t -test, Lesion vs. NAWM: ∗ , p < 0.01; ∗ ∗ , p < 0.05. 
Table 3A 
Multiple sclerosis: NAA, NAAG, tNAA and Ins. 
Concentration, mmol/L CRLB 
Metabolite Lesion, mean (sd) n NAWM, mean (sd) n Lesion, mean (sd) NAWM, mean (sd) 
Ins 8.1 (1.4) 11 7.28 (1.2) 11 2.73 (0.6) 3.09 (0.3) 
NAA 8.94 (1.1) 11 9.69 (0.9) 11 2.55 (0.5) 2.36 (0.5) 
NAAG 2.09 (0.6) 11 2.55 (0.9) 11 8 (2.5) 7 (2.9) 
















































































 = 0.503; GM mm 3 , MS vs AQP4Ab-NMOSD: 370.5 ± 253.4 vs 281.8
 158.5, p = 0.519) ( Zhang et al., 2001 ). 
.3. Differences in neurochemical profiles between NAWM and lesions in 
S 
Next, we investigated neurochemical differences between lesions
nd NAWM. In the MS group absolute tNAA was lower in lesions com-
ared to NAWM ([NAWM tNAA] – [lesion tNAA]: 1.21 ± 1.31 mmol/L
mean ± SD); permutation-based one-sample t(10) = 2.91, p = 0.042,
ohen’s d = 0.878). We then wanted to investigate whether this dif-
erence in tNAA was driven by a decrease in NAAG, or NAA, or both.
here was a trend towards lower NAAG in lesions compared to NAWM
[NAWM NAAG] – [lesion NAAG]: 0.46 ± 0.57 mmol/L; permutation-
ased one-sample t(10) = 2.52, p = 0.095, Cohen’s d = 0.760), and no sig-
ificance found for NAA differences ([NAWM NAA] – [lesion NAA]: 0.75
 1.13 mmol/L; permutation-based one-sample t(10) = 2.10, p = 0.160,
ohen’s d = 0.634) ( Fig. 2 and Table 3A ). Again, there was a trend to-
ards greater myo -Inositol in MS lesions versus NAWM ([lesions Ins]
[NAWM Ins]: 0.82 ± 0.99 mmol/L; t(10) = 2.62; p = 0.078, Cohen’s
 = 0.790; Fig. 2 & Table 3A ). See Supplemental Table 3 for a summary
f all metabolites. 
.4. No difference in neurochemical profiles between NAWM and lesions in
QP4ab-nmosd 
With permutation-based t-tests of NAWM and lesion metabolite con-
entration differences, within the AQP4Ab-NMOSD patients, we found
o difference in tNAA (note that this is n = 4; [NAWM tNAA]-[ lesion
 NAA]: 1.48 ± 2.06 mmol/L (mean ± sd); permutation-based one-sample
(3) = 1.24, p = 0.625, Cohen’s d = 0.621). When the two metabolites
hat contribute to tNAA were investigated individually, neither NAA nor
AAG differed between NAWM and lesions, despite NAAG being visi-
ly greater in NAWM ([NAWM NAA]–[ lesion NAA]: 0.79 ± 1.84 mmol/L;
ermutation-based one-sample t(3) = 0.74, p = 0.875, Cohen’s d = 0.372;
NAWM NAAG]-[ lesion NAAG]: 0.69 ± 0.3 mmol/L; permutation-based
ne-sample t(3) = 3.96, p = 0.250, Cohen’s d = 1.979) (See Fig. 2 ). Myo -
nositol did not differ between NAWM and lesioned tissue ([NAWM
ns] – [lesion Ins]: − 0.63 ± 0.78 mmol/L; permutation-based one-sample
(3) = − 1.40, p = 1.000, Cohen’s d = − 0.700) (see Fig. 2 & Table 3B ). There
ere thus no differences in either tNAA, NAA, NAAG or myo -Inositol be-
ween the lesion and NAWM groups in AQP4Ab-NMOSD. 5 .5. Visibly greater tNAA in NAWM in MS compared with 
QP4Ab-NMOSD 
We then wanted to compare neurochemical concentrations between
S and AQP4Ab-NMOSD. Permutation-based unpaired two-sample t-
ests were used. NAWM concentrations of NAA and NAAG were not
ower in MS NAWM (AQP4Ab-NMOSD vs MS NAWM, NAA: 8.69
 0.7 mmol/L vs 9.69 ± 0.9 mmol/L; permutation-based two-sample
(13) = 1.7912, p = 0.466, Cohen’s d = 1.046; AQP4Ab-NMOSD vs MS
AWM NAAG: 2.19 ± 0.3 mmol/L vs 2.55 ± 0.9 mmol/L; permutation-
ased two-sample t(13) = 0.7316, p = 0.985, Cohen’s d = 0.427). Visual
nspection of the data revealed greater tNAA in MS compared to NMOSD
AWM, but this did not reach significance (AQP4Ab-NMOSD vs MS
AWM tNAA: 10.89 ± 0.4 mmol/L vs 12.24 ± 0.9 mmol/L; permutation-
ased two-sample t(13) = 2.7458, p = 0.108, Cohen’s d = 1.603). 
Myo -Inositol was not greater in MS versus AQP4AB-NMOSD lesions
MS vs AQP4Ab-NMOSD Ins: 8.1 ± 1.4 mmol/L vs 7.86 ± 1.3 mmol/L;
wo-sample t(13) = 0.268, p = 1.000, Cohen’s d = 0.157) ( Fig. 2 ). 
For completeness, we tested for a significant interaction of site
NAWM / lesion) by group (MS / AQP4Ab-NMOSD) for NAA, NAAG,
NAA and Ins (including our a priori expectations regarding the direc-
ion of difference) and this was non-significant for all comparisons (all
 > 0.9). 
.6. Ins:NAA correlates with clinical score in AQP4Ab-NMOSD 
Finally, we wished to investigate whether there were any relation-
hips between our metabolites of interest and disease scores (See sup-
lemental figure 3). Of relationships previously reported in the liter-
ture, we demonstrated a striking linear correlation between NAWM
ns:NAA and EDSS for both MS and AQP4Ab-NMOSD (MS: R 2 = 0.22,
QP4Ab-NMOSD: R 2 = 0.91, respectively; R 2 = 0.30 combined). Post-hoc
ests, uncorrected for multiple comparisons, showed that this was sig-
ificant for the pooled data (AQP4Ab-NMOSD + MS NAWM Ins:NAA ∝
DSS: r(13) = 0.55, p = 0.033) and for AQP4Ab-NMOSD alone (AQP4Ab-
MOSD NAWM Ins:NAA ∝ EDSS; r(2) = 0.95; p = 0.048), but not for MS
lone (MS NAWM Ins:NAA ∝ EDSS: r(9) = 0.47, p = 0.141). 
We additionally explored the relationship between Ins:NAA, disease
roup (MS / AQP4Ab-NMOSD) and MRS site (lesion / NAWM) with post-
oc two-tailed t-tests (uncorrected for multiple comparisons). We found
hat lesion Ins:NAA was significantly greater than NAWM Ins:NAA in
S (MS lesion Ins:NAA vs NAWM Ins:NAA: 0.91 ± 0.10 vs 0.76 ± 0.12;
ne-sample t(10) = 5.42, p = 0.001) but for all other comparisons was
on-significant. 
G. Tackley, Y. Kong, R. Minne et al. NeuroImage 238 (2021) 118225 
Fig. 2. Individual metabolite comparison boxplots. 
Boxplot representations of metabolite comparisons. 
p-values generated with bidirectional permutation-based t-tests. 
MS, multiple sclerosis; NMO, AQP4Ab-positive neuromyelitis optica spectrum disorder; NAWM, normal appearing white matter; L, lesion. 
(Figure produced with R ggplot2 package; Wickham, 2016 ). 
Table 3B 
AQP4-Ab positive neuromyelitis optica spectrum disorder: NAA, NAAG, tNAA and Ins. 
Concentration, mmol/L CRLB 
Metabolite Lesion, mean (sd) n NAWM, mean (sd) n Lesion, mean (sd) NAWM, mean (sd) 
Ins 7.86 (1.3) 4 7.23 (0.8) 4 2.75 (0.4) 3 (0) 
NAA 7.9 (2.2) 4 8.69 (0.7) 4 2.5 (0.5) 2.5 (0.5) 
NAAG 1.5 (0.2) 4 2.19 (0.3) 4 9.25 (2.9) 7.5 (2.7) 
tNAA 9.4 (2.3) 4 10.89 (0.4) 4 2 (0) 1.75 (0.4) 













I  . Discussion 
This study was performed in order to investigate the patterns of neu-
ochemical changes in lesioned tissue and in normal appearing white
atter in multiple sclerosis (MS) and aquaporin-4 antibody positive neu-
omyelitis optica spectrum disorder (AQP4Ab-NMOSD). To do this, we
cquired Magnetic Resonance Spectroscopy (MRS) data using a seven6 esla (7T) MRI system, with the inherent benefit of increased spectral
ispersion. We demonstrated significant differences in water T2 relax-
tion times between lesions and NAWM, which we corrected for in sub-
equent analyses. 
Using this corrected data, as expected, Total NAA (tNAA) was lower
n MS lesions compared to MS NAWM with a trend towards greater myo -
nositol in MS lesions compared to MS NAWM, in line with historical




1 Ins in lesions: MS > NMOSD 
2 tNAA in NAWM: NMOSD > MS 
3a tNAA in MS: NAWM > lesion 
3b tNAA in NMOSD: NAWM > lesion 
4a Ins in MS: lesion > NAWM 


















































































































I  RS studies that attribute these features respectively to the axonal loss
nd gliosis seen in MS lesions ( Arnold et al., 1992 ; Davie et al., 1994 ).
e demonstrated no differences between lesion and NAWM in AQP4Ab-
MOSD patients, and no differences in either NAA or myo -Inositol be-
ween MS and AQP4Ab-NMOSD lesions. We did show, however, a re-
ationship between NAA:Ins, commonly thought to be a marker of neu-
onal loss and gliosis, and clinical disability score, in both groups com-
ined and AQP4Ab-NMOSD alone ( Llufriu et al., 2014 ; Miller DH, 2014 ).
.1. Optimised MRS allowed us to address important confounds 
A number of parameters were optimised to acquire our 7T MRS spec-
ra. The STEAM sequence was chosen despite the loss of half of the avail-
ble signal to minimize relaxation effects using a short echo time. Trans-
erse relaxation differences between lesion sites and NAWM at longer
Es have the potential to confound the quantification of metabolite con-
entrations. 
The achieved spectral quality (high spectral resolution, SNR, ef-
cient water suppression, and a distortionless baseline) allowed reli-
ble quantification of 17–18 metabolites in periventricular white matter
VOI = 15 × 15 × 15 mm 3 ) using LCModel analysis. T2-water relaxation
imes were significantly higher in lesioned tissue as confirmed in previ-
us studies ( Laule et al., 2007b , 2007a ), and quantifies what one would
xpect given their features on T2-weighted images where lesions are
dentified clinically by their bright (hyperintense) appearance. 
We avoided over-reliance on metabolite ratios (e.g. tNAA:tCr) and
orrected for multiple T2-relaxation components. The former is of par-
icular importance within neuroinflammatory conditions because a par-
llel loss of tCr in damaged tissue may conceal tNAA loss when expressed
s tNAA:tCr ( Davies et al., 1995 ). Accurate absolute quantification of
etabolites, powerful in their own right, also allow for meaningful in-
erpretation of metabolite ratios where applied. 
.2. NAA-G may drive lower tNAA in MS lesions versus NAWM 
A decrease in NAA in MS lesions has long been described
 Arnold et al., 1992 ; Davie et al., 1994 ). However, a number of questions
ave remained to be conclusively answered about this finding, which we
an begin to address here. 
Our optimised MRS methodology allowed us to accurately quantify
nd separate tNAA into its constituent parts: NAA and NAA-G. Although
hese two neurochemicals have similar molecular structures, meaning
hat they are hard to distinguish using MRS, they have distinct func-
ional roles. The role of NAA is not entirely clear, but is a reflection of
euronal mitochondrial function, and has been hypothesised to have a
ole in myelination ( Birken and Oldendorf, 1989 ; Moffett et al., 2007 ).
AAG, the most abundant peptide in the central nervous system, is
ound in both neurones and glia, acts as both a neurotransmitter and
 glutamate reservoir, and is higher in white matter compared to grey
atter ( Chiew et al., 2018 ; Neale et al., 2000 ). NAAG in MS NAWM
ay reflect glial cell number and may also have a neuroprotective role
ia its ability to activate the metabotropic glutamate receptor, mGluR.
s discussed further under Section 4.4 below, it is possible that higher
AWM versus lesion tNAA is a reflection of up-regulated NAAG in NAWM
s well as loss of NAAG (and NAA) in lesions and could be interpreted
s a response to disease activity ( Vrenken et al., 2005 ). The statistical7 ignificance of MS NAWM NAA and NAAG differences presented in the
esults is conservative, that is, it is corrected for multiple comparisons
nd corrected for both directions of change. When we inspect the unidi-
ectional (one-tailed) permutation-type t -test (still corrected for multiple
etabolite comparisons) aligned in direction with our a priori hypoth-
sis, the lower NAAG in lesions achieves a p-value of 0.049 and adds
urther weight to the NAAG upregulation argument expounded above. 
.3. No differences in NAA or myo -inositol between lesions and NAWM in 
QP4Ab-nmosd patients 
Within our four AQP4Ab-NMOSD patients, no differences were found
etween lesion and NAWM sites for NAA, tNAA or Ins. Interpretation of
hese results is of course difficult given the small number of AQP4Ab-
MOSD patients in this study. However, to our knowledge there is only
ne other study describing AQP4Ab-NMOSD MRS findings in central
ervous system lesions and that study focuses solely on the spinal cord
 Ciccarelli et al., 2013 ). Ciccarelli and colleagues found lower myo -
nositol in AQP4Ab-NMOSD lesions relative to MS lesions which in
urn had lower concentrations than healthy controls, and they hypoth-
sised that this demonstrated astrocyte loss. There are no brain studies
f AQP4Ab-NMOSD lesions versus NAWM for appropriate comparison
nd assumptions about AQP4Ab-NMOSD brain lesion metabolites from
pinal cord data should be made with caution, especially given that no
QP4Ab-NMOSD NAWM site was sampled in Ciccarelli’s study and no
ealthy control group was sampled in ours. It must also be noted that
oth ours and Ciccarelli’s studies have low numbers of AQP4Ab-NMOSD
articipants (4 and 5, respectively). 
.4. No evidence for MS and AQP4Ab-NMOSD metabolite differences 
Our a priori assumptions about AQP4Ab-NMOSD and MS lesion and
AWM site differences were not confirmed. Conversely, an unexpected
ifference noted in plotted data suggested tNAA was greater in MS com-
ared to AQP4Ab-NMOSD NAWM, but this did not reach significance.
ow tNAA in MS in contrast to AQP4Ab-NMOSD NAWM is usually of-
ered as support for the hypothesis that MS pathogenesis involves a
hronic extra-lesional neurodegenerative processes that is absent from
QP4Ab-NMOSD pathology ( Huda et al., 2019 ). However, this finding
as been challenged by Vrenken et al. who found that the only signif-
cant difference between healthy controls and MS NAWM was a differ-
nce in NAAG (and not tNAA or NAA), and that NAAG wasn’t lower in
AWM of MS patients but was instead raised compared to healthy con-
rols ( Vrenken et al., 2005 ). This explanation better fits with our data
nd is supported by a recent study of healthy participants, in whom
bsolute tNAA NAWM concentrations are lower than in MS NAWM
ere, and more in line with our AQP4Ab-NMOSD tNAA NAWM values
~8.7 mmol/L for 20–60 year olds) ( Ding et al., 2016 ). 
Again, contrary to our initial hypothesis, we did not find greater
yo -Inositol in MS lesions compared with AQP4Ab-NMOSD lesions. It
s not clear why this might be, and interpreting a null result in an n
f 4 should be treated with caution, but it may be that this reflects the
nown pathology of some chronic AQP4Ab-NMOSD lesions where a pe-
iod of gliosis supervenes over the astrocytic death of the acute lesion
tage ( Lucchinetti et al., 2014 ). MRS myo -Inositol has been previously
uggested as a potential differentiator for MS and AQP4Ab-NMOSD be-
ause astrocytes are reduced pathologically in AQP4Ab-NMOSD and in-
reased in MS ( Geraldes et al., 2018 ), but this assumption rests on data
rom the only study besides ours to have performed MRS in AQP4Ab-
MOSD lesions, and that study was in spinal cord lesions not brain le-
ions ( Ciccarelli et al., 2013 ). 
One explanation for the different myo -Inositol concentrations be-
ween Ciccarelli et al ’s study and the results presented here is that we
ave studied lesions of different ages: our study examined older lesions
ore likely to be in the gliotic stage (4–24 months vs 43–116 months).
t is also possible that spinal cord lesions are in general more destructive





























































































































han brain lesions, leading to astrocyte loss, whereas brain lesions are
ommonly more subtle, non-demyelinating, non-necrosing and some-
imes reversible (indeed, historically, brain lesions were thought to be
typical of AQP4Ab-NMOSD)( Lucchinetti et al., 2014 ; Pittock et al.,
006 ). Finally, AQP4Ab-NMOSD lesions in the cord are centred on grey
atter, while those in the brain are found primarily in white matter,
hich may be an important factor in gliosis ( Lucchinetti et al., 2014 ). 
Reassuringly, we found no difference in average WM/GM partial-
olume in NAWM voxels between diseases. However, lesion volume esti-
ates were on average greater in AQP4Ab-NMOSD compared to MS (MS
s AQP4Ab-NMOSD, 466mm 3 ± 365 vs 897mm 3 ± 442, permutation-
ype t -test: p = 0.06; see Supplemental Table 2) meaning NAWM con-
ribution within an MRS lesion voxel will likely impact on metabolite
oncentrations and should be taken into account when interpretating
QP4Ab-NMOSD and MS lesion voxel comparisons (hypothesis 1) and
ithin MS lesion and NAWM differences (hypothesis 4a). 
Whether certain metabolic differences (e.g. NAAG or Ins), within or
utside of lesions (or combined) can be used to differentiate MS and
QP4Ab-NMOSD has been the aspiration of many neuroinflammatory
RS studies and although our data holds no firm conclusions on this,
e hope it aids hypothesis development in future studies. 
.5. Ins:NAA correlates with disability 
We also found a correlation between Ins:NAA and disability (as as-
essed by EDSS), which was significant on post-hoc testing for both
isease groups combined and for AQP4Ab-NMOSD alone (Supplemen-
al figure 3). This correlation suggests that higher Ins:NAA relates to
orse clinical score. Consistent with this finding, NAWM Ins:NAA has
een shown in one study of MS patients to predict subsequent clinical
isability, with higher Ins:NAA predicting greater EDSS score increase
 Llufriu et al., 2014 ). It has been hypothesised that the CNS immune pro-
ess in MS leads to an increase of myo -inositol and the neurodegenera-
ion causing long-term disability results in reduced NAA, hence Ins:NAA
s greater in more destructive and longer-lasting disease ( Llufriu et al.,
014 ; Miller DH, 2014 ). We found a similar association of Ins:NAA and
DSS across the whole group, but this was primarily driven by the strong
elationship between Ins:NAA and EDSS in AQP4Ab-NMOSD NAWM (al-
eit in n = 4). This is surprising, as the received wisdom is that AQP4Ab-
MOSD NAWM is relatively free from damage, at least outside the optic
erve and cortico-spinal tracts ( Aboul-Enein et al., 2010 ; Bichuetti et al.,
008 ; De Seze et al., 2010 ; Matthews et al., 2015 ). However, even if
nly small differences in NAWM NAA and myo -Inositol occur, provided
he differences decrease in magnitude with increasing EDSS, Ins:NAA
ill increase proportionally with EDSS. In our four AQP4Ab-NMOSD
atients we found no-change or a slight increase in NAA with EDSS (i.e.
o evidence of neuronal loss in NAWM in line with existing literature),
long with a proportionally greater increase in Ins. 
.6. Limitations 
Our study sought to compare AQP4Ab-NMOSD and MS neurochem-
cals using MRS, but has some limitations. 
Firstly, no healthy control population was used as a comparator for
AWM brain voxels. Instead, patients’ own NAWM was used as a control
ite to compare with lesion sites. This approach was chosen as we wished
o determine differences between lesioned and non-lesion tissue in our
roups. It also allowed us to avoid the difficulties of precisely matching
oxel location between participants and needing to control confounding
actors such as age, gender, ethnicity and medication history, which can
ave a substantial effect on neurochemical levels. As such, however, it
s impossible to be sure whether the differences between lesioned and
on-lesioned tissue shown here are driven by pathological changes in
esions or in non-lesioned tissue, or both, except through comparison
ith previously published values, which have invariably used different
echniques and assessed different anatomical locations. 8 It is also possible that a structured difference in sampling location
ither by disease or voxel type (lesion/NAWM) might have biased the
ndings, given that we know MRS measures differ slightly across differ-
nt lobes of the brain ( Ding et al., 2016 ). However, there were no sys-
ematic differences in voxel location between lesioned and non-lesioned
issue in either of the groups studied, making this potential source of bias
ess concerning when interpreting our results. 
Secondly, there is MRS and MRI diffusion imaging evidence of
irror changes (tNAA:tCr and apparent diffusion coefficient, respec-
ively) that occur contralaterally to sites of lesions in multiple sclero-
is ( Stefano et al., 1999 ; Werring et al., 2000 ). These could conceivably
educe the magnitude of lesion versus NAWM differences investigated
ere, or hide them altogether. 
Thirdly, lesions were all at least 3 months old (i.e. chronic) at the
ime of assessment. This makes our results comparable with most but
ot all previous MS MRS lesion studies but means little insight can be
ained into changes with lesion progression. 
Fourthly, AQP4Ab-NMOSD disproportionately affects Afro-
aribbean individuals, whereas MS is commonly considered a disease
f Caucasians. As such, matching ethnicity is difficult for studies
omparing these two patient groups. It is not clear what effect, if any,
his would have on the data. Whether a difference in disability between
iseases influences the observed NAWM tNAA differences could also be
valuated in larger samples. 
Finally, our participant numbers were low, especially for our
QP4Ab-NMOSD group ( n = 4) and conclusions regarding metabolic
ifferences within AQP4Ab-NMOSD and between diseases are impossi-
le to validate. However, AQP4Ab-NMOSD is extremely rare and thus
e believe these data remain of utmost importance. In Denmark, which
as one of the highest reported incidences of NMOSD, there are less
han 4 people diagnosed with NMO per 1000,000 per year. UK-wide
revalence of NMOSD is unknown, but is likely less than 20 per million
 Hor et al., 2020 ). Around 60% of these will have brain lesions at some
oint during their disease course ( Pittock et al., 2006 ). This, in con-
ert with the restrictions placed on 7T scanning (especially relevant in
 chronically co-morbid population), the practicalities of moving often
ighly disabled individuals into scanners, and the problem of tolerating
xtended periods in the MRI scanner for participants who commonly
uffer high levels of chronic pain ( Kanamori et al., 2011 ), meant that
nly a few of our small national cohort could be scanned. As such re-
ults are presented with effect sizes and thus will be readily incorporated
nto future meta-analyses. 
. Conclusion 
Here we present results from an early, comprehensive metabolite
rofile of MS and AQP4Ab-NMOSD chronic lesions and normal ap-
earing white matter acquired using magnetic resonance spectroscopy
MRS) at 7T. The study utilises an optimised methodology, including
orrection for multiple T2-water relaxation times, and our results are
roadly in line with previous MRS studies in neurodegerative condi-
ions, but serve to highlight some under-explored subtleties in MRS
rofiles, such as the absence of myo -Inositol concentration differences
n AQP4Ab-NMOSD brain lesions versus NAWM and the influence of
AAG differences between lesions and normal appearing white matter.
e hope that the technique described here will be highly relevant for
uture 7T MRS studies of this sort. 
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